{
  "guideline": {
    "id": "PA166265141",
    "name": "Annotation of DPWG Guideline for allopurinol and HLA-B",
    "source": "DPWG",
    "version": 6,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265141",
    "relatedChemicals": [
      {
        "id": "PA448320",
        "name": "allopurinol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299109",
      "name": "Recommendation PA166299109",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448320",
          "name": "allopurinol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061472,
        "html": "<ul>\n<li>\n<p>Choose an alternative, such as febuxostat</p>\n</li>\n<li>\n<p>Another option is to induce allopurinol tolerance first: To induce allopurinol tolerance, the allopurinol dose is increased every 3 days until a dose of 100 mg/day has been achieved on Day 28. The consecutive daily doses in the\ninduction protocol are 50 µg, 100 µg, 200 µg, 500 µg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg.</p>\n</li>\n</ul>\n"
      },
      "implications": [
        "A strongly increased risk of developing the life-threatening cutaneous side effects Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and DRESS is present in\npatients with this genetic variation. The risk of an allopurinol-induced life-threatening cutaneous side effect (mortality 11%) in these patients is 1.6-2.0% for the entire group\nand 8-18% for the group with chronic renal insufficiency."
      ],
      "lookupKey": {
        "HLA-B": "*58:01 positive"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "36056234",
      "title": "Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.",
      "authors": [
        "van der Pol Karel H",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne Marie",
        "Guchelaar Henk-Jan",
        "Risselada Arne",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van der Weide Jan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "Houwink Elisa J F",
        "Rongen Gerard A"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2022
    }
  ],
  "version": "2023-12-19-10-38"
}